Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
vaccines
Biotech
Pfizer pens $530M deal to use Novavax adjuvant on 2 programs
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the pharma’s vaccine programs.
James Waldron
Jan 20, 2026 10:40am
ARPA-H director eyes future beyond vaccines
Jan 20, 2026 5:00am
mRNA coalition demands stable FDA leadership amid vaccine changes
Dec 5, 2025 1:36pm
Fierce Healthcare
CDC updates website to promote debunked vaccine-autism link
Nov 20, 2025 4:20pm
Moderna norovirus trial heads north again in hunt for cases
Nov 6, 2025 8:04am
Sanofi drops toddler RSV vaccine after ph. 3 heads for failure
Oct 24, 2025 7:00am